大肠杆菌
毒力
微生物学
志贺毒素
生物
柠檬酸杆菌
病菌
基因沉默
肠杆菌科
痢疾志贺氏菌
毒素
细菌
岩藻糖
大肠杆菌感染
肠道菌群
毒力因子
基因
抗生素
发病机制
质粒
志贺氏菌
沙门氏菌
作者
Guozhen Ma,R. T. Liu,Xueping Li,Jialin Wu,Yuanyuan Niu,Sheng Wang,Ziwei Chen,Xudong Qin,Qian Wang,Junyue Wang,Jiamin Qian,Mingqing Zhang,Yu Pang,Yamin Sun,Guosheng Tang,Tao Wang,Yutao Liu
标识
DOI:10.1038/s41467-026-69126-4
摘要
Enterohemorrhagic Escherichia coli (EHEC) is a severe foodborne pathogen that can lead to hemolytic uremic syndrome. However, antibiotics are contraindicated for EHEC treatment due to toxin release and gut microbiota disruption. Here we report a dual‑mechanism therapeutic strategy combining an engineered Escherichia coli Nissle 1917 strain (EcN3) with 2′‑fucosyllactose (2‑FL) delivered via multicompartment microspheres (MCMs). EcN3 expresses α‑L‑fucosidase to hydrolyze 2‑FL into lactose and fucose. Lactose enhances glucuronic acid utilization, limiting a preferred nutrient of EHEC, whereas fucose activates FusKR signaling to suppress virulence gene expression. MCMs confer gastric protection and enable targeted colonic release, ensuring coordinated activity. In female mouse models and infant rabbit models of Citrobacter rodentium and EHEC infection, this system reduces intestinal colonization, virulence gene expression and epithelial damage without inducing Shiga toxin production. Moreover, MCMs-based strategy preserves the relative abundance of Lactobacillus, and promotes intestinal integrity. This targeted strategy presents a viable alternative to antibiotics, addressing EHEC pathogenesis and antibiotic resistance. Enterohemorrhagic Escherichia coli (EHEC) is a foodborne pathogen where therapeutic antibiotic treatment can release toxins and disrupt gut microbiota. Here the authors demonstrate a therapeutic strategy where an engineered Escherichia coli Nissle 1917 limits the glucuronic acid utilization by EHEC.
科研通智能强力驱动
Strongly Powered by AbleSci AI